Biognosys and Moderna present a joint poster at the mRNA Health Conference Boston

Exploring the potential of using targeted proteomics for the high throughput quantification of protein expression after mRNA administration

Last week Biognosys attended the 4th International mRNA Health Conference in Boston, MA. With more than 300 participants this annual event is a leading forum dedicated to the expanding field of therapeutic messenger RNA (mRNA).

Biognosys and Moderna Therapeutics presented a joint poster entitled “LC-MRM, a rapid tool for high throughput quantification of protein target expression after mRNA administration”. The study was focused on exploring the potential of using Biognosys’ targeted proteomics technology for the high throughput quantification of protein target expression after mRNA administration. Results show that targeted proteomics is well suited for determining the mRNA therapeutic variant that yields the highest protein amount in mammalian cells. In addition, the method has demonstrated a high specificity for quantifying proteins with high sequence similarities.

Targeted proteomics is a mass spectrometry based method for peptide and protein quantification. Biognosys targeted proteomics workflows allow absolute label-free quantification of more than 100 proteins per run analyzed in a high-throughput mode in thousands of samples. 

The poster is now available for download (here).

Enjoy reading!

×

Let us help you do great proteomics!

Please click here to contact us.